Search results
The dengue vaccine protects against all four types of dengue. The vaccine is safe and effective among children who have previously had dengue. The vaccine has few side effects. The most common side effects are soreness, itchiness, or pain in the injection site, headaches, lack of energy, and general discomfort.
- Transmission
Through mosquito bites. Dengue viruses are spread to people...
- Dengue Vaccination
A vaccine can help prevent dengue, which is caused by four...
- Dengue Vaccine Recommendations
Persons with moderate or severe acute illness with or...
- Vaccine Eligibility & Recommendations
People can be infected with dengue multiple times. For...
- Transmission
- Key Facts
- Who Should Get A Dengue Vaccine?
- Where Does Dengue Commonly occur?
- Who Should Not Get A Dengue Vaccine?
- What Type of Dengue Vaccine Is available?
- How Well Do These Vaccines Work?
- What Are The Possible Side Effects of The Dengue Vaccine?
- Where Can I Find This Vaccine?
- How Can I Get Help Paying For This Vaccine?
One type of dengue vaccine is available for use in areas with risk of dengue in the United States: 1. Dengvaxia® dengue vaccine
CDC recommends dengue vaccination for children 9 through 16 years old, but only when they have been previously infected with dengue and living in areas where dengue is common. This previous infection should be confirmed by laboratory testing. This vaccine is different from other vaccines in that it is only recommended for people who have already be...
Dengue is common in the U.S. territories of American Samoa, Puerto Rico, and the U.S. Virgin Islands, and the freely associated states, including the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.
The vaccine should not be administered to 1. Children under 9 years of age 1.1. Children under 9 years of age are less likely to have had a prior dengue infection. For this reason, if your child is under the age of 9, they are not eligible for dengue vaccination. 2. People over 16 years of age 2.1. The dengue vaccine is not licensed for people over...
One type of dengue vaccine is available in the United States. The Dengvaxia vaccine will be available starting in 2022 for use in children 9 through 16 years old with laboratory-confirmed evidence of a previous dengue virus infection and living in areas where dengue is common (occurs frequently or continuously). Dengue is common in the U.S. territo...
Overall, Dengvaxia protects children from dengue illness, hospitalizations, and severe dengue 8 out of 10 times (80%) in children who had dengue before vaccination. The vaccine protects against all four dengue virus types: dengue 1, 2, 3, and 4.
For children who HAVE already had dengue 1. The most common side effects include soreness, itchiness, or pain in the injection site, headaches, lack of energy, and general discomfort. These side effects are normal signs that the body is building protection, and the side effects should go away within a few days. 2. People sometimes faint after medic...
Your child’s healthcare provider is usually the best person to discuss recommended vaccines for your child. These vaccines are part of the routine childhood immunization schedule. Vaccines for children and teens are available at: 1. Community health clinics If your healthcare provider does not have these vaccines for children, ask for a referral. V...
Most health insurance plans cover routine vaccinations. The Vaccines for Children (VFC) program also provides vaccines for children 18 years and younger who are uninsured, underinsured, Medicaid-eligible, American Indian, or Alaska Native.
May 14, 2024 · Key points. A vaccine can help prevent all four dengue viruses (serotypes). Dengvaxia is the only dengue vaccine approved for use in the United States. The dengue vaccine is recommended for routine use among children aged 9–16 years with laboratory-confirmed previous dengue virus infection and living in areas where dengue is endemic.
Feb 2, 2024 · Stephanie Soucheray, MA. Dengue. Sesai/ Flickr cc. Results of a phase 3 trial in the New England Journal of Medicine ( NEJM) show 80% protection for the single-dose tetravalent (four-strain) Butantan-Dengue Vaccine (Butantan D-V) among participants with no evidence of previous dengue exposure and 89% protection in those with a history of exposure.
